Sense and sensibility to early combine bevacizumab to radiation treatment of brain metastasis: reply to Lou and Sperduto

We thank Lou and Sperduto (1) for their comments regarding the results of our REBECA trial [a phase I study designed to assess the safety of bevacizumab (BEV) in combination with whole brain radiation therapy (WBRT) for brain metastases (BM) of solid tumors (2)]. They highlighted the interest of exploring VEGF-based therapy in the context of radiation therapy of BM, as well as the issues of such an approach.